Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Peak ALC after CAR-T infusion predicts clinical response in aggressive lymphoma

Radhika Bansal • 5 Jun 2022
ASCO 2022
Multiple Myeloma

Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, talks on the association between peak absolute lymphocyte count (ALC) after CAR-T infusion and clinical response in aggressive lymphoma. A higher absolute lymphocyte ALC peak was associated with increased complete response rates and a longer duration of response in the first 6 months post-CAR-T cell infusion. Increasing ALC levels also correlated with CAR-T cell expansion and higher rates of progression-free survival (PFS) and overall-survival (OS). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Radhika Bansal

2:22
Outpatient management of CAR-T therapy in multiple myeloma and lymphoma
Radhika Bansal • 9 Dec 2023
1:49
Outpatient management of patients with multiple myeloma treated with bispecific antibodies
Radhika Bansal • 9 Dec 2023
2:00
Prognostic tool to identify CAR-T outcomes in patients with aggressive lymphoma
Radhika Bansal • 11 Dec 2022
2:23
Prophylactic dexamethasone use with CAR-T therapy: real-world practice and outcomes
Radhika Bansal • 11 Dec 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals